Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs

US10793545B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Ulrich Bothe · Berlin, DE
• Holger Siebeneicher · Berlin, DE
• Nicole SCHMIDT · San Francisco, US
• Reinhard NUBBEMEYER · Berlin, DE
• Ulf Bömer · Glienicke, DE
• Judith Günther · Berlin, DE
• Holger STEUBER · Berlin, DE
• Martin Lange · Berlin, DE
• Christian Stegmann · Berlin, DE
• Andreas SUTTER · Berlin, DE
• Alexandra RAUSCH · Berlin, DE
• Christian FRIEDRICH · Brandenburg, DE
• Peter Hauff · Berlin, DE

Key dates

• Filing date: Apr 5, 2019
• Grant date: Oct 6, 2020
• Expiry date: Apr 5, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F7/1804
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.